|Articles|September 24, 2015
Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer
Author(s)Lecia V. Sequist
Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
Advertisement
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ASCO 2026 That Patients Should Know
2
Lynch Syndrome: Why Upper Endoscopies and Colonoscopy Prep Save My Life
3
Pumitamig Shows 70% Response in Advanced Lung Cancer Regardless of PD-L1 Status
4
How a Teen Cancer Survivor and Her Best Friend Created an App to Help Patients Between Appointments
5